

## Special Issue

# Clinical Application of Proton Therapy and Advanced Radiotherapy in Gynecological Cancer

### Message from the Guest Editors

Radiotherapy is pivotal in the definitive treatment of gynecological cancers: as curative intent in locally advanced cervical cancer with brachytherapy and vaginal cancers; as post-operative therapy in endometrial, cervical and vulval cancers, and for isolated recurrences such as para-aortic or other regional nodal or bone recurrence. Intensity-modulated radiotherapy emerges as the new gold standard compared to the conventional four-field “box” technique, with merits in reducing acute and late gastrointestinal and urinary toxicities. Proton or heavy-particle therapy is now being investigated as a superior modality, with studies demonstrating dosimetric improvement, especially in a post-operative setting and extended field para-aortic irradiation. This Special Issue aims to illustrate current clinical experience in the latest image-guided radiotherapy or proton therapy applications across gynecological cancer applications.

### Guest Editors

Dr. Amy Tien Yee Chang

Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong

Dr. Bin Yang

Medical Physics Department, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong

### Deadline for manuscript submissions

30 June 2026



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/254492](https://mdpi.com/si/254492)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)